Fig. 2: Cumulative incidence curves for the incidence of persistent HPV in the modified intention-to-treat primary analyses. | Nature Medicine

Fig. 2: Cumulative incidence curves for the incidence of persistent HPV in the modified intention-to-treat primary analyses.

From: Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results

Fig. 2

Cumulative incidence curves were computed by vaccine group using Kaplan–Meier methods. Two-sided log-rank P values were computed for each comparison using the log-rank test. a, Cumulative incidence of persistent HPV 16/18 in the HPV 16/18 mITT cohort (n = 1,458). Four participants in the HPV 16/18 mITT cohort did not contribute a second end-point swab and thus did not contribute time at risk. b, Cumulative incidence of persistent HPV 16/18/31/33/45/52/58 in the HPV 16/18/31/33/45/52/58 mITT cohort (n = 615). One participant in the HPV 16/18/31/33/45/52/58 mITT cohort did not contribute a second end-point swab and thus did not contribute time at risk.

Back to article page